128108-06-5

Upstream product

• 99-33-2 3,5-dinitrobenoyl chloride 
• 5394-63-8 2,2,6-trimethyl-4H-1,3-dioxin-4-one 
• 135088-97-0 methyl (2R,3S)-2-(3,5-dinitrophenylcarbonylamino)-3-hydroxybutanoate 

Downstream Products

• 250330-30-4 (1S,2R)-2-(3,5-dinitrophenylcarbonylamino)-2-methoxycarbonyl-1-methylethyl 3-aminocrotonate 
• 250330-32-6 (1S,2R)-2-(3,5-dinitrophenylcarbonylamino)-2-methoxycarbonyl-1-methylethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate 
• 250330-31-5 (1S,2R)-2-(3,5-dinitrophenylcarbonylamino)-2-methoxycarbonyl-1-methylethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate 

Relevant academic research and scientific papers

Syntheses, calcium channel agonist-antagonist modulation activities, nitric oxide release, and voltage-clamp studies of 2-nitrooxyethyl 1,4-dihydro-2,6-dimethyl- 3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate enantiomers

The novel (-)-(S)-2 and (+)-(R)-3 enantiomers of 2-nitrooxyethyl 1,4-dihydro-2,6-dimethyl- 3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate were synthesized for evaluation as calcium channel modulators. Determination of their in vitro calcium-cha

The design of (-)-(S)-2-nitrooxyethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxyla te: A cardioselective positive inotropic derivative of Bay K 8644

The title compound, (-)-(S)-9, is a novel cardioselective calcium channel modulator that exhibits a calcium channel agonist effect on heart, a weak calcium channel antagonist effect on smooth muscle, and releases nitric oxide in vitro. (-)-(S)-9 is a usef